For instance, folate-targeted paclitaxel–fisetin nanoparticles downregulated ABCG2 and triggered apoptosis in resistant ovarian cells [178], whereas NanoOrl, an orlistat-loaded formulation, restored taxane sensitivity via fatty acid synthase inhibition, independent of P-gp in prostate cancer [179]. Here, FASN is linked to prostate carcinoma.